Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $537.74, for a total value of $5,108,530.00. Following the completion of the transaction, the chief executive officer owned 40,513 shares in the company, valued at approximately $21,785,460.62. This represents a 19.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

United Therapeutics Trading Up 1.1%

UTHR stock opened at $544.33 on Wednesday. The stock has a market capitalization of $23.11 billion, a P/E ratio of 20.09, a price-to-earnings-growth ratio of 1.75 and a beta of 0.57. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35. The firm has a 50-day moving average price of $563.19 and a 200-day moving average price of $524.62.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same period last year, the firm posted $6.63 earnings per share. As a group, equities analysts predict that United Therapeutics Corporation will post 26.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on UTHR. Cantor Fitzgerald upped their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday, March 12th. Royal Bank Of Canada reduced their price objective on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Bank of America boosted their price objective on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 31st. Morgan Stanley set a $516.00 target price on United Therapeutics in a research report on Thursday, May 7th. Finally, TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $619.42.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of UTHR. Torren Management LLC acquired a new stake in shares of United Therapeutics in the fourth quarter valued at about $26,000. Activest Wealth Management lifted its stake in shares of United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 56 shares during the period. Entrust Financial LLC bought a new stake in United Therapeutics in the fourth quarter valued at approximately $31,000. International Assets Investment Management LLC boosted its holdings in United Therapeutics by 426.7% in the first quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 64 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB increased its position in United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 49 shares during the period. 94.08% of the stock is owned by institutional investors.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.